EpiVario Patents

Patent portfolio assigned to EpiVario (verified via public assignee records). Estimated patent count: 2. Biotech spun out of UPenn Epigenetics Institute; ACSS2 inhibitors for memory-related psychiatric disease (PTSD, addiction). USPTO granted US Patent 12,077,527 (plus Japan JP7423068B2) to EpiVario for ACSS2 inhibitors. Licensor: University of Pennsylvania (in-license); ReEngage Therapeutics is an out-licensee partner (cancer indications). These are licensing relationships, not paying customers.